Published Studies Related to Travatan (Travoprost)
A short-term randomized clinical trial of daily versus alternate day use of
travoprost 0.004% in the treatment of ocular hypertension. 
in lowering the intraocular pressure (IOP) in patients with ocular hypertension... CONCLUSIONS: Alternate day use of travoprost 0.004% was as safe and effective as
Travoprost 0.004%/timolol 0.5%-fixed combination with and without benzalkonium chloride: a prospective, randomized, doubled-masked comparison of safety and efficacy. [2011.09]
PURPOSE: The purpose of this study is to compare the safety and intraocular pressure (IOP)-lowering efficacy of travoprost/timolol in a benzalkonium chloride (BAK)-free fixed combination preserved with polyquaternium-1 (TRA/TIM BAK-free), with travoprost/timolol-fixed combination preserved with BAK (TRA/TIM), in patients with open-angle glaucoma or ocular hypertension... CONCLUSION: Travoprost/timolol BAK-free demonstrated equivalence to travoprost/timolol preserved with BAK in efficacy. No clinically relevant differences in the safety profiles of travoprost/timolol BAK-free and travoprost/timolol preserved with BAK were identified.
The comparison of the effects of latanoprost, travoprost, and bimatoprost on central corneal thickness. [2011.08]
PURPOSE: To compare the effects of latanoprost, travoprost, and bimatoprost on central corneal thickness (CCT)... CONCLUSIONS: Topical therapy with prostaglandin analogues is associated with CCT reduction. Latanoprost, travoprost, and bimatoprost have a similar effect on CCT.
A 12-week, double-masked, parallel-group study of the safety and efficacy of travoprost 0.004% compared with pilocarpine 1% in Chinese patients with primary angle-closure and primary angle-closure glaucoma. [2011.08]
OBJECTIVE: To examine the intraocular pressure-lowering efficacy and safety of travoprost 0.004% and pilocarpine 1% in Chinese patients with primary angle-closure (PAC) and primary angle-closure glaucoma (PACG) after laser iridotomy in China... CONCLUSIONS: Travoprost 0.004% once daily provides effective IOP-lowering efficacy with significantly greater IOP reduction from baseline when compared with pilocarpine 1% 4 times daily at 4 PM over the 12-week period. Travoprost 0.004% once daily is safe and well tolerated in PAC or PACG patients.
Timolol versus brinzolamide added to travoprost in glaucoma or ocular hypertension. [2011.07]
BACKGROUND: To compare the efficacy and safety of timolol 0.5% versus brinzolamide 1.0% when added to travoprost monotherapy in patients with primary open-angle glaucoma or ocular hypertension... CONCLUSION: Both adjunctive combinations moderately reduced IOP in patients inadequately controlled with travoprost monotherapy, with timolol being slightly stronger 8 hours after instillation. Adjunctive treatment with brinzolamide and travoprost may be an alternative for patients not tolerant or not responsive to treatment with timolol and travoprost.
Clinical Trials Related to Travatan (Travoprost)
Study of Patient Use and Perception of the Travatan Dosing Aid [Completed]
The primary objective of this study is to determine the opinions of patients who are given
the Travatan Compliance Monitoring Dispenser to use to dispense their Travatan glaucoma
Three Month Safety and Efficacy Study of TRAVATAN´┐Ż Versus Travoprost Ophthalmic Solution, 0.004% [Not yet recruiting]
A multi-center, observer-masked, randomized, parallel group efficacy and safety study of
TRAVATAN« versus a new formulation of Travoprost Ophthalmic Solution, 0. 004%
Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN´┐Ż Z) or Bimatoprost 0.01% [Recruiting]
Subjects are dosed once daily with either TRAVATAN«Z or LUMIGAN« at 8PM for 6 weeks and then
are switched for a further 6 weeks to the other product either TRAVATAN«Z or LUMIGAN«. The
primary efficacy variable: To demonstrate non-inferiority in the Intraocular Pressure (IOP)
lowering efficacy of travoprost 0. 004% (TRAVATAN« Z) to that of bimatoprost 0. 01% after 6
weeks of treatment. Secondary efficacy variable: To detect a difference in IOP lowering
efficacy of travoprost 0. 004% (TRAVATAN« Z) and bimatoprost 0. 01% measured at individual
time points post dose after 6 weeks of treatment.
AR-12286 Fixed Dose Combination [Not yet recruiting]
This is a double-masked, randomized, controlled study assessing the safety and ocular
hypotensive efficacy of two AR 12286/travoprost fixed-dose combination products compared to
Travatan« Z in patients with elevated intraocular pressure
An Efficacy and Tolerability Study of TRAVATAN´┐Ż Versus LUMIGAN´┐Ż [Recruiting]
Reports of Suspected Travatan (Travoprost) Side Effects
Intraocular Pressure Increased (16),
Visual Acuity Reduced (16),
Cystoid Macular Oedema (10),
Vision Blurred (8),
Drug Ineffective (7),
Ocular Hyperaemia (6),
Visual Impairment (5),
Glaucoma (4), more >>